Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
05 2022
Historique:
received: 01 02 2022
revised: 12 04 2022
accepted: 12 04 2022
pubmed: 22 4 2022
medline: 4 5 2022
entrez: 21 4 2022
Statut: ppublish

Résumé

The aim of this study was to evaluate the long-term safety of the omission of immediate neck dissections (IND) in patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) achieving a less than complete nodal response on 12-week FDG PET-CT. Patients with HPV-positive, node-positive HNSCC that were treated with radical (chemo) radiotherapy (RT) between January 2013 and September 2019 were identified. PET-CT responses were classified as complete (CR), incomplete (ICR) or equivocal (EQR) nodal responses. Clinical outcomes were obtained. 347 patients were identified. Median follow-up was 43.9 (IQR, 30.8-61.2) months. 62.8% (218/347) achieved a CR, 23.4% (81/347) EQR and 13.8% (48/347) ICR nodal response. 70 of 81 (86.4%) patients with an EQR and 25 of 48 (52.1%) with an ICR had no residual disease during follow up (a pathologically negative ND if surgery undertaken or no subsequent neck or distant relapse clinically/radiologically). Median survival of the EQR and CR groups were not reached, and despite the omission of IND in 95% of the EQR group there was no statistically significant differences in overall survival (OS) between the groups, p = 1.0. Median survival of ICR was not reached. However, OS for ICR group was significantly worse than that of CR, and EQR, both p < 0.001. The omission of IND in those achieving an EQR nodal response does not compromise long-term survival. This supports the safety of extended surveillance in patients with HPV-positive disease and an EQR on 12-week FDG PET-CT.

Sections du résumé

BACKGROUND AND AIM
The aim of this study was to evaluate the long-term safety of the omission of immediate neck dissections (IND) in patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) achieving a less than complete nodal response on 12-week FDG PET-CT.
MATERIAL AND METHODS
Patients with HPV-positive, node-positive HNSCC that were treated with radical (chemo) radiotherapy (RT) between January 2013 and September 2019 were identified. PET-CT responses were classified as complete (CR), incomplete (ICR) or equivocal (EQR) nodal responses. Clinical outcomes were obtained.
RESULTS
347 patients were identified. Median follow-up was 43.9 (IQR, 30.8-61.2) months. 62.8% (218/347) achieved a CR, 23.4% (81/347) EQR and 13.8% (48/347) ICR nodal response. 70 of 81 (86.4%) patients with an EQR and 25 of 48 (52.1%) with an ICR had no residual disease during follow up (a pathologically negative ND if surgery undertaken or no subsequent neck or distant relapse clinically/radiologically). Median survival of the EQR and CR groups were not reached, and despite the omission of IND in 95% of the EQR group there was no statistically significant differences in overall survival (OS) between the groups, p = 1.0. Median survival of ICR was not reached. However, OS for ICR group was significantly worse than that of CR, and EQR, both p < 0.001.
CONCLUSION
The omission of IND in those achieving an EQR nodal response does not compromise long-term survival. This supports the safety of extended surveillance in patients with HPV-positive disease and an EQR on 12-week FDG PET-CT.

Identifiants

pubmed: 35447564
pii: S1368-8375(22)00159-2
doi: 10.1016/j.oraloncology.2022.105870
pii:
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105870

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Chief Scientist Office
Pays : United Kingdom

Informations de copyright

Crown Copyright © 2022. Published by Elsevier Ltd. All rights reserved.

Auteurs

Suyun Zhou (S)

The Beatson West of Scotland Cancer Centre, Glasgow, UK.

Christopher Chan (C)

University Hospital Ayr, Ayr, UK.

Robert Rulach (R)

University of Glasgow, Glasgow, UK.

Hesham Dyab (H)

West of Scotland PET Centre, Gartnavel General Hospital, Glasgow, UK.

Fraser Hendry (F)

West of Scotland PET Centre, Gartnavel General Hospital, Glasgow, UK.

Carole Maxfield (C)

West of Scotland PET Centre, Gartnavel General Hospital, Glasgow, UK.

Mary-Frances Dempsey (MF)

West of Scotland PET Centre, Gartnavel General Hospital, Glasgow, UK.

Allan James (A)

The Beatson West of Scotland Cancer Centre, Glasgow, UK.

Derek Grose (D)

The Beatson West of Scotland Cancer Centre, Glasgow, UK.

Carolynn Lamb (C)

The Beatson West of Scotland Cancer Centre, Glasgow, UK.

Stefano Schipani (S)

The Beatson West of Scotland Cancer Centre, Glasgow, UK.

Christina Wilson (C)

The Beatson West of Scotland Cancer Centre, Glasgow, UK.

Yee Cheng Lau (Y)

Greater Glasgow and Clyde NHS Trust, Glasgow, UK.

Claire Paterson (C)

The Beatson West of Scotland Cancer Centre, Glasgow, UK. Electronic address: Claire.Paterson2@ggc.scot.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH